Hydroxymethylglutaryl-CoA Reductase Inhibitors
"Hydroxymethylglutaryl-CoA Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.
| Descriptor ID |
D019161
|
| MeSH Number(s) |
D27.505.519.186.071.202.370 D27.505.519.389.370 D27.505.954.557.500.202.370
|
| Concept/Terms |
Hydroxymethylglutaryl-CoA Reductase Inhibitors- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hydroxymethylglutaryl CoA Reductase Inhibitors
- Inhibitors, Hydroxymethylglutaryl-CoA Reductase
- Reductase Inhibitors, Hydroxymethylglutaryl-CoA
- Inhibitors, HMG-CoA Reductase
- Inhibitors, HMG CoA Reductase
- Reductase Inhibitors, HMG-CoA
- HMG-CoA Reductase Inhibitors
- HMG CoA Reductase Inhibitors
- Statins, HMG-CoA
- HMG-CoA Statins
- Statins, HMG CoA
- Inhibitors, Hydroxymethylglutaryl-CoA
- Hydroxymethylglutaryl-CoA Inhibitors
- Inhibitors, Hydroxymethylglutaryl CoA
- Statins
- Inhibitors, Hydroxymethylglutaryl-Coenzyme A
- Hydroxymethylglutaryl-Coenzyme A Inhibitors
- Inhibitors, Hydroxymethylglutaryl Coenzyme A
|
Below are MeSH descriptors whose meaning is more general than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
This graph shows the total number of publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in this website by year, and whether "Hydroxymethylglutaryl-CoA Reductase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2006 | 4 | 3 | 7 |
| 2007 | 5 | 1 | 6 |
| 2008 | 6 | 1 | 7 |
| 2009 | 4 | 0 | 4 |
| 2010 | 2 | 1 | 3 |
| 2011 | 2 | 0 | 2 |
| 2012 | 2 | 0 | 2 |
| 2013 | 8 | 0 | 8 |
| 2014 | 5 | 1 | 6 |
| 2015 | 10 | 3 | 13 |
| 2016 | 11 | 5 | 16 |
| 2017 | 8 | 1 | 9 |
| 2018 | 7 | 1 | 8 |
| 2019 | 7 | 0 | 7 |
| 2020 | 2 | 1 | 3 |
| 2021 | 1 | 1 | 2 |
| 2022 | 4 | 0 | 4 |
| 2023 | 2 | 0 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Profiles.
-
Adherence to cardiovascular medications and risk of cardiovascular disease in breast cancer patients: A causal inference approach in the Pathways Heart Study. PLoS One. 2024; 19(9):e0310531.
-
Telephone-based social health screening by pharmacists in the nonadherent Medicare population. J Manag Care Spec Pharm. 2023 Nov; 29(11):1184-1192.
-
Use of Tenofovir Alafenamide Fumarate for HIV Pre-Exposure Prophylaxis and Incidence of Hypertension and Initiation of Statins. JAMA Netw Open. 2023 09 05; 6(9):e2332968.
-
Projected Outcomes of Optimized Statin and Ezetimibe Therapy in US Military Veterans with Coronary Artery Disease. JAMA Netw Open. 2023 Aug 01; 6(8):e2329066.
-
Performance of the pooled cohort equation in South Asians: insights from a large integrated healthcare delivery system. BMC Cardiovasc Disord. 2022 12 23; 22(1):566.
-
Statins Utilization in Adults With HIV: The Treatment Gap and Predictors of Statin Initiation. J Acquir Immune Defic Syndr. 2022 12 15; 91(5):469-478.
-
Modest effect of statins on fasting glucose in a longitudinal electronic health record based cohort. Cardiovasc Diabetol. 2022 Jul 14; 21(1):132.
-
A Randomized, Double-Blinded, Placebo-Controlled Trial of Simvastatin to Prevent Recurrent Pancreatitis. Pancreas. 2022 01 01; 51(1):e10-e12.
-
Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study. J Am Heart Assoc. 2021 10 19; 10(20):e020377.
-
Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE). Am Heart J. 2021 05; 235:54-64.